Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos recently acquired U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and Provista's proprietary commercial-stage Videssa® breast cancer blood test.
Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.
Todos has entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The agreements cover multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies.
Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.
Todos has entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The agreements cover multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies.
Location: United States, New York
Employees: 11-50
Founded date: 2010
Investors 1
| Date | Name | Website |
| - | The Yozma ... | korea.yozm... |
Mentions in press and media 27
| Date | Title | Description |
| 04.10.2022 | ROTH Capital Partners to Host Inaugural Healthcare Opportunities Conference on October 6th at the Yale Club in New York City | Event to feature company presentations and one-on-one meetings between institutional investors and senior management from select Healthcare companies in Biotechnology, Pharmaceuticals, Medical Technologies, Oncology and Mental Health Therap... |
| 24.06.2022 | Todos Medical Releases Preliminary Data from IRB-Waived Tollovid® Market Research Study in Acute and Long COVID | “We are pleased with the preliminary results from this sponsored market research study, that show the majority of our customers are satisfied with Tollovid,” said Dr. Dorit Arad, Founder and Chief Scientific Officer at 3CL Pharma. NEW YORK ... |
| 24.06.2022 | Todos Medical Releases Preliminary Data from IRB-Waived Tollovid® Market Research Study in Acute and Long COVID | 83% of respondents with Acute COVID were satisfied; and 68% of respondents with Long COVID were satisfied Todos Medical, Ltd. (OTCQB:TOMDF) We are pleased with the preliminary results from this sponsored market research study, that show the... |
| 19.01.2022 | Pepperdine University Hosts the 22nd Annual Celebrity Flag Football Challenge®, Presented by Todos Medical's Tollovid® | In support of First Responders, Military Service Members and Boys and Girls Youth Groups MALIBU, CALIFORNIA, Jan. 19, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Working along with the NFL Host Committee, Celebrity Sweat®, the #1 celebrity... |
| 13.12.2021 | Todos Medical Enters 90-Day Extension of Agreement with Convertible Note Holders on Moratorium on Conversions of Convertible Notes | NEW YORK, NY, ALPHARETTA, GA and TEL AVIV, ISRAEL, Dec. 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced the Company has e... |
| 07.12.2021 | Todos Medical Announces 2 New COVID-19 PCR Testing Reference Lab Agreements for CLIA/CAP Lab Provista Diagnostics | Combined testing from two contracts averages 1,000 PCR samples per day Testing potential for the two contracts could ramp up to 5,000 PCR samples per day New York, NY, Alpharetta, GA and Tel Aviv, ISRAEL, Dec. 07, 2021 (GLOBE NEWSWIRE) -- v... |
| 02.12.2021 | Todos Medical Announces All 31 Patients Enrolled to Date in Tollovir® Phase 2 Clinical Trial in Hospitalized COVID-19 Patients Have Completed Study Participation | Dr. Jules Mitchel now leading preparation for data lock and statistical analysis Business update call Today at 4:30PM EST New York, NY, and Tel Aviv, ISRAEL, Dec. 02, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: ... |
| 30.11.2021 | Todos Medical Confirms SARS-CoV-2 PCR Test Kits Used at CLIA/CAP Lab Provista Diagnostics Detect Omicron Variant | Provista to also utilize Osang’s High-Capacity Reflex Variant PCR Detection Kit that has been confirmed to identify the Omicron variant New York, NY, and Tel Aviv, ISRAEL, Nov. 30, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical,... |
| 29.11.2021 | Todos Medical Enters into Binding Agreement to Acquire All 3CL Protease Biology-Related Assets and Intellectual Property from NLC Pharma | Company to form majority owned subsidiary, 3CL Sciences, an entity focused on the development of variant-agnostic COVID-19 antivirals such as Tollovir that utilize the 3CL protease related IP Dr. Dorit Arad, pioneering biology researcher re... |
| 25.11.2021 | Todos Medical Announces Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. for Tollovid Products Covering 30 Countries in Europe | NEW YORK & TEL AVIV, Israel - Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, together with its joint venture partner NLC Pharma, Ltd., announced that it has entered into an exclusi... |
Show more